"FDA guidance are pretty clear about what is and is not a copy," Brunner said
October 17, 2025: New Lawsuits Filed Against Mounjaro and Eli Lilly As of October 2025, there are now 2,809 active lawsuits in the federal litigation against Mounjaro and other GLP-1 drugs
Some preclinical work has also reported preserved or enhanced lean muscle for example, greater grip strength in aged mice when combined with exercise [7]

Razzaki TS, Weiner A, Shukla AP Therapeutics and Clinical Risk Management 2022, 18:955-964 Published Date: 28 September 2022 Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview Telci Caklili O, Cesur M, Mikhailidis DP, Rizzo M Diabetes, Metabolic Syndrome and Obesity 2023, 16:1767-1774 Published Date: 14 June 2023 The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis Lv X, Wang H, Chen C, Zhao Y, Li K, Wang Y, Wang L, Fu S, Liu J Diabetes, Metabolic Syndrome and Obesity 2024, 17:701-714 Published Date: 12 February 2024 Analysis Using Various Models on the Effect of Metabolic Surgery on Cardiovascular Disease Risk in the Chinese Population with Obesity Wang Z, Xu G, Chen G, Amin B, Wang L, Li Z, Wang J, Chen W, Yu C, Tian C, Wuyun Q, Sang Q, Shang M, Lian D, Zhang N Diabetes, Metabolic Syndrome and Obesity 2024, 17:2457-2468 Published Date: 17 June 2024 Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study Cetiner S Diabetes, Metabolic Syndrome and Obesity 2026, 19:594898 Published Date: 31 March 2026

However, the oral form has fewer long-term trials than the injectable version, which has been on the market for 14 years